Wave Life Sciences Ltd. (NASDAQ: WVE) announced that the Singapore High Court will hear its application on April 29, 2026, regarding the company's proposed redomiciliation from Singapore to the United States.

The biotechnology company filed its application on April 16, 2026, seeking court approval to convene a shareholder meeting for the scheme of arrangement under Section 210 of Singapore's Companies Act 1967. The hearing is scheduled for 10:00 am Singapore time at 1 Supreme Court Lane.

The Singapore High Court has established deadlines for responses, requiring any affidavits in response to be submitted by 4:00 pm Singapore time on April 22, 2026. Written submissions or bundle of authorities must be filed by 4:00 pm Singapore time on April 24, 2026.

Wave Life Sciences has indicated that materials filed with the application and related court directions will be available on the corporate governance section of its investor relations website.

The redomiciliation process requires approval from both Wave shareholders and the Singapore High Court. The company previously filed a preliminary proxy statement on April 15, 2026, and expects to file a definitive proxy statement with the Securities and Exchange Commission.

Wave Life Sciences is a clinical-stage biotechnology company focused on RNA medicines, with programs targeting obesity, alpha-1 antitrypsin deficiency, and liver disease. The company is headquartered in Cambridge, Massachusetts.